文献速递小儿眼科与斜弱视

基于眼动追踪的双眼光学家庭治疗用于弱视:一项多中心随机临床试验

An Eye-Tracking-Based Dichoptic Home Treatment for Amblyopia: A Multicenter Randomized Clinical Trial.
PubMed 文献 · Ophthalmology · 2022-10-26

这项前瞻性、多中心、随机、设盲、对照、非劣效性关键性试验将103名4至不足9岁的弱视儿童按1:1随机分配至CureSight双眼治疗组或遮盖组。CureSight组每天90分钟、每周5天、持续16周(共120小时),遮盖组每天2小时、每周7天(共224小时)。结果显示CureSight组弱视眼视力改善0.28 logMAR,遮盖组改善0.23 logMAR,达到预设的1行非劣效性界值;CureSight组治疗依从性显著更高(91% vs 83%),未发现严重不良事件。

要点

  • CureSight组弱视眼视力改善0.28 logMAR,遮盖组改善0.23 logMAR,非劣效性成立。
  • CureSight组依从性91%,显著高于遮盖组的83%(P=0.011)。
  • 两组立体视和双眼视力改善无显著差异,未报告严重不良事件。

核心结论

  • 双眼治疗在4至不足9岁弱视儿童中耐受良好,且不劣于遮盖治疗。
  • 高依从性可能为弱视提供一种替代治疗选择。

研究设计与样本

  • 前瞻性、多中心、随机、设盲、对照、非劣效性关键性试验,共纳入103名4至不足9岁弱视儿童。
  • 受试者按1:1随机分配至CureSight双眼治疗组或遮盖组。
  • CureSight治疗使用组合式红蓝眼镜和眼动追踪器,在双眼分视流媒体视频内容中于非弱视眼中心凹周围诱导实时模糊。
  • CureSight组每天使用设备90分钟、每周5天、持续16周(共120小时);遮盖组每天遮盖2小时、每周7天(共224小时)。
  • 预设非劣效性界值为1行。

主要发现

  • CureSight组弱视眼视力改善0.28±0.13 logMAR(P<0.0001),遮盖组改善0.23±0.14 logMAR(P<0.0001),差异的90%置信区间为-0.008至0.076。
  • 双眼治疗组立体视改善0.40 log弧秒(P<0.0001),双眼视力改善0.13 logMAR(P<0.0001)。
  • 遮盖组立体视改善0.40 log弧秒(P<0.0001),双眼视力改善0.09 logMAR(P<0.0001)。
  • 两组立体视改善差异为0(95%置信区间-0.27至-0.27;P=0.76),双眼视力改善差异为0.041(95%置信区间-0.002至0.085;P=0.07),均无显著差异。
  • 双眼治疗组依从性显著高于遮盖组(91% vs 83%;95%置信区间-4.0%至21%;P=0.011),未发现严重不良事件。

关键数值与推荐

  • 主要结局为弱视眼视力改善,采用重复测量协方差分析建模。
  • 预设非劣效性界值为1行。
  • 次要结局包括立体视、双眼视力和治疗依从率,组内采用单样本Wilcoxon检验,组间采用双样本Wilcoxon检验。
  • 安全性结局包括研究相关不良事件的发生频率和严重程度。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Comparing visual outcomes after use of a novel binocular eye-tracking-based home treatment (CureSight; NovaSight, Ltd) with patching. DESIGN: Prospective, multicenter, randomized, masked, controlled, noninferiority pivotal trial. PARTICIPANTS: One hundred three children 4 to < 9 years with anisometropic, small-angle strabismic or mixed-mechanism amblyopia were randomized 1:1 to either CureSight treatment or patching. METHODS: The CureSight treatment uses combined anaglyph glasses and an eye tracker to induce real-time blur around the fellow eye fovea in dichoptic streamed video content. Participants used the device for 90 minutes/day, 5 days/week for 16 weeks (120 hours). The patching group received 2 hours of patching 7 days/week (224 hours). The prespecified noninferiority margin was 1 line. MAIN OUTCOME MEASURES: The primary outcome was the improvement in the amblyopic eye visual acuity (VA), modeled with a repeated measures analysis of covariance. Secondary outcomes included stereoacuity, binocular VA, and treatment adherence rates, analyzed by a 1-sample Wilcoxon test within each group and a 2-sample Wilcoxon test comparing groups. Safety outcomes included the frequency and severity of study-related adverse events (AEs). RESULTS: CureSight group VA improvement was found to be noninferior to patching group improvement (0.28 ± 0.13 logarithm of the minimum angle of resolution [logMAR] [P < 0.0001] and 0.23 ± 0.14 logMAR [P < 0.0001], respectively; 90% confidence interval [CI] of difference, -0.008 to 0.076). Stereoacuity improvement of 0.40 log arcseconds (P < 0.0001) and improved binocular VA (0.13 logMAR; P < 0.0001) were observed in the binocular treatment group, with similar improvements in the patching group in stereoacuity (0.40 log arcseconds; P < 0.0001) and binocular VA (0.09 logMAR; P < 0.0001), with no significant difference between improvements in the 2 groups in either stereoacuity (difference, 0; 95% CI, -0.27 to -0.27; P = 0.76) or binocular VA (difference, 0.041; 95% CI, -0.002 to 0.085; P = 0.07). The binocular treatment group had a significantly higher adherence than the patching group (91% vs. 83%; 95% CI, -4.0% to 21%; P = 0.011). No serious AEs were found. CONCLUSIONS: Binocular treatment was well tolerated and noninferior to patching in amblyopic children 4 to < 9 years of age. High adherence may provide an alternative treatment option for amblyopia. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Wygnanski-Jaffe T, Kushner BJ, Moshkovitz A, et al. An Eye-Tracking-Based Dichoptic Home Treatment for Amblyopia: A Multicenter Randomized Clinical Trial. Ophthalmology. 2022. PMID: 36306974. doi:10.1016/j.ophtha.2022.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。